Arctic Bioscience AS (9TD) Stock Statistics & Valuation Metrics

Arctic Bioscience AS has a market cap or net worth of €7.40M. The enterprise value is ―.

Arctic Bioscience AS has 26,956,257 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arctic Bioscience AS’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -15.25%.

The current PE Ratio of Arctic Bioscience AS is ―. Arctic Bioscience AS’s PEG ratio is ―.

In the last 12 months, Arctic Bioscience AS had revenue of 40.10M and earned -41.03M in profits. Earnings per share was -1.52.

In the last 12 months, operating cash flow was -22.65M and capital expenditures -7.14M, giving a free cash flow of -29.79M billion.

Arctic Bioscience AS pays an annual dividend of ―, resulting in a dividend yield of ―

Arctic Bioscience AS upcoming earnings date is Aug 27, 2026, TBA (Not Confirmed).

Arctic Bioscience AS as a current ratio of 0.59, with Debt / Equity ratio of 35.92%

In the past 12 months, Arctic Bioscience AS has paid 0.00 in taxes.

Arctic Bioscience AS EV to EBITDA ratio is -4.51, with an EV/FCF ratio of -3.29.

Arctic Bioscience AS has €1.29M in cash and marketable securities with €32.86M in debt, giving a net cash position of -€61.03M billion.

Gross margin is -26.74%, with operating margin of -89.71%, and net profit margin of -102.32%.

The average price target for Arctic Bioscience AS is ―, which is 11.43% higher than the current price. The consensus rating is ―